

New patent approval in China strengthens the AroCell patent portfolio

AroCell are glad to announce that the Chinese Patent Office has confirmed the grant of a patent (patent application number: 202080032513.4) to AroCell AB for an invention on the detection and classification of respiratory infections.

The European Patent Office had previously granted the patent application (EP3966568) in July 2024, strengthening our position in the EU market. In September 2024, the Japanese Patent Office (patent application number: 2021-564698) also followed suit. This patent relates to using serum thymidine kinase 1 (STK1) to predict the presence and diagnosis of Mycoplasma pneumonia caused by M. pneumoniae. Furthermore, STK1 protein levels aid in the classification of respiratory infections by Mycoplasma pneumonia, viral pneumonia, or bacterial pneumonia.

The Chinese patent approval further strengthens the AroCell patent portfolio. Even though AroCell's main focus is urology, this patent approval in the EU, Japan, and China allows us to explore clinical applications of TK 210 ELISA in respiratory infections.

Contacts

Anders Hultman, CEO
Phone: +46 (0) 8 799 67 50
E-mail: anders.hultman@arocell.com

About Thymidine Kinase 1

Thymidine Kinase 1 (TK1) is a key enzyme in DNA precursor synthesis. It is up-regulated during the S phase of the cell cycle and degraded in mitosis. Its presence in cells indicates active cell proliferation. Increased levels of TK1 in the blood can indicate abnormal cell turnover or disruption of cells in active proliferation triggered by, for example, therapeutic agents.

About AroCell

AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, AroCell uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; www.arocell.com

Press Release
14 February 2025 09:30:00 CET



Attachments

[New patent approval in China strengthens the AroCell patent portfolio](#)